United States
- IHS Capabilities
- Industry Solutions
-
Products & Services
-
IHS CERA
Leading strategy advisors to international energy companies, governments and financial institutions More
-
Standards & Regulations
IHS provides technical standards, codes & specifications plus the tools to manage critical data More
-
EHS&S Solutions
IHS helps companies meet their EHS&S goals with the most deployed enterprise software solution More
-
-
Current Insights
-
Current Insights
IHS covers global industry & economic insight and analysis to advance client business decisions More
-
- Events
- About
Events
Share | 
- Home
- Events
- WebCasts / Webinars
- Private Equity Investors Webinar - December 2011
Private Equity Investors Webinar - How Private Equity Investors are Evolving to Stay Ahead of the Curve
IHS Chemical is hosting the How Private Equity Investors are Evolving to Stay Ahead of the Curve Webinar on December 1, 2011
Thursday December 1, 2011
Start time: 10 AM EST / 3 PM GMT / 4 PM CET
End time: 11 AM EST / 4 PM GMT / 5 PM CET
During this live webcast you will learn about Investment Opportunities in the Chemicals Industry:
- economic trends impacting capital expenditure and growth in the chemical industry
- competitive landscape across various chemical industry subsectors
- innovation and sustainability in the chemical industry
- and private equity investment in chemicals – past, present and future.
Discussion during the webcast also will focus on accelerating value creation in portfolio investments and will draw on practical experiences in the following areas; minimizing “day one” disruption – planning and execution; business & technology innovation to create superior returns; accelerating speed to value while reducing investment risk; and preparing for investment monetization events.
-
David Pleasance, Senior Consulting Partner, Deloitte Consulting
David Pleasance
Senior Consulting Partner, Deloitte Consulting
David is focused on leading client relationships in the chemicals and related process manufacturing industries. He has over 30 of experience working in these industries. David has been the chief architect of business strategies and led transformation programs with many global process manufacturing companies focused on strengthening competitive positioning, reshaping business portfolios, leveraging core technologies into ancillary markets and accelerating business expansion. This has included optimizing business operations in the areas of supply chain reengineering, production and manufacturing optimization, pricing strategy, customer relationship management, finance function effectiveness and enterprise risk management.
David has also advised private equity clients in the structuring of numerous M&A transactions and led the subsequent integration and transformation of the businesses. Through this work he has developed and applied an innovative “life cycle” service delivery approach which has been highly successful in accelerating and enhancing value creation while lowering portfolio investment risk
Larry Stern, former Chairman and CEO of Talecris Biotherapeutics
Larry Stern
former Chairman and CEO of Talecris Biotherapeutics
As the Chairman and CEO of Talecris Biotherapeutics, Lawrence (Larry) Stern, led the evaluation and plan that resulted in the formation of Talecris in 2005 with financial support from two private equity groups to acquire the Bayer Biologics plasma business. Larry guided the company’s transformation into an independent, industry leading global provider of plasma-derived protein therapies culminating in the company’s 2009 IPO and listing on NASDAQ. In 2010, Larry was recognized as the national winner of Ernst and Young’s Entrepreneur of the Year in Health Sciences.
Larry started his career at ARCO Chemical in 1981 where he built his skill base for 15 years in research, development and manufacturing before moving into management. He joined Bayer Corporation as the president of its Urethanes group in 2000 upon Bayer’s acquisition of Lyondell Chemical’s polyol business. Larry left Bayer in 2003 to pursue private-equity ventures, and was then able to leverage his experience at Bayer to be the successful acquirer of their Biologics’ plasma business.
To change the font size, press Ctrl and (- or +)
To change the font size, Ctrl + (- or +)
If that didn’t work, try the following:
Microsoft Internet Explorer
- From the View menu, select Text Size
- Select an option from Smallest to Largest
Firefox or Netscape
- From the View menu, select Zoom or Text Size
- Select Increase or Decrease
Google Chrome
- Click the wrench icon next to the address bar.
- Next to Zoom, select + or -